Humanized mouse and rat models are specialized research tools that incorporate functional human genes, cells, tissues, and organs for use in biological and medical research. These models are employed to mimic the human immune system under both healthy and diseased conditions. These humanized mouse and rat models find applications in various areas, including fundamental research, safety assessments for large molecule therapies, emulation of certain human-specific infectious diseases, and the evaluation of the effectiveness of immunotherapy methods. They achieve this by expressing human proteins while suppressing the corresponding mouse proteins in both cells and tissues.

Humanized mouse and rat models serve as invaluable resources for conducting preclinical testing, enabling the replication of human pathological conditions, the assessment of compound efficacy, and the measurement of their impact on human proteins.

Global Humanized Mouse and Rat Model market was valued US $255 Mn in 2022 and is expected to reach ~US $465 Mn by 2032, growing at a CAGR of 6.2% during the forecast period 2023-2032.

The Humanized Mouse and Rat Model market is experiencing growth primarily due to several key drivers, including a rising number of research initiatives employing humanized models, an expanding demand for personalized medicine, a surge in research and development activities within pharmaceutical and biotechnology firms, and sustained backing through investments and grants from both government and private sectors.

COVID -19 Impact on Humanized Mouse and Rat Model Market

The COVID-19 pandemic has had a notable impact on the market for humanized mouse and rat models used in biomedical research. The pandemic prompted a surge in research related to infectious diseases, including COVID-19. Humanized mouse and rat models played a critical role in studying the virus, its transmission, and potential treatments. As a result, there was an increased demand for these models in laboratories and research facilities worldwide. Many research institutions redirected their focus and resources toward COVID-19 research, potentially leading to a temporary shift away from other areas of research that typically rely on humanized mouse and rat models. This shift in priorities may have caused fluctuations in demand for these models.

The pandemic disrupted global supply chains, affecting the production and distribution of laboratory animals, including humanized mouse and rat models. Delays and shortages in the availability of these models may have impacted research timelines and projects. Government funding for research, including grants related to humanized mouse and rat models, may have been redirected or prioritized towards COVID-19 research efforts, affecting funding availability for other projects. he pandemic has accelerated certain trends in biomedical research, such as the development of mRNA-based vaccines. These advancements may influence the long-term research directions and priorities in the field of humanized mouse and rat models.

Factors Driving the Humanized Mouse and Rat Model Market

Drivers

Rising demand for personalized medicine

As researchers increasingly seek more accurate disease models that closely mirror human physiology for non-clinical studies and drug discovery, the demand for humanized mouse and rat models is expected to surge. Particularly, there is a growing demand for humanized mouse models in immuno-oncology research, driven by the increasing validation of their effectiveness in research studies.

To gain a deeper understanding of adaptive immunity and human innate immunity, the development of next-generation humanized mouse models is currently underway. These advancements are poised to significantly advance oncology research. Consequently, market players are actively diversifying their portfolios to cater to various research applications.

For instance, THE JACKSON LABORATORY in the United States offers the hu-CD34 (Humanized CD34+) mouse platform, designed for in vivo analysis of the efficacy and safety of novel therapies that modulate the immune system. Similarly, genOway in France provides established humanized models for allergy and inflammation studies in mice, which are well-suited for assessing the in vivo efficacy and safety of therapeutic candidates and biologics.

Biomarkers specific to each individual are harnessed to tailor treatments in the realm of precision medicine, often referred to as personalized medicine. In the pursuit of creating patient-specific cancer models, researchers have turned to mice, where immune-compromised mice are injected with components from a patient's tumor, resulting in the generation of PDX models. Each mouse then follows a unique treatment regimen, effectively shaping distinct plans for reducing tumors in patients. The adoption of humanized mouse models is expected to further drive the demand for personalized medication.

The Jackson Laboratory, for instance, has developed over 450 different PDX oncology mouse models for a range of diseases, including acute myeloid leukemia (AML), as well as bladder, breast, lung, pancreatic, and ovarian malignancies. The field of customized medicine has seen accelerated progress due to advancements in scientific research, associated tools, and technologies. These factors are projected to propel the expansion of the humanized mouse model market in the years to come.

Challenge

Alternatives available for using animals in testing

In response to the increasing demand for humanized mouse models and mounting pressure from animal rights organizations to discontinue animal experimentation, researchers are actively exploring alternatives to traditional human study models. The use of animals in research comes with inherent drawbacks, including the need for specialized personnel, lengthy experimental protocols, and high costs. To study conditions like diabetes, researchers are employing a range of methods and non-traditional species.

These alternatives encompass rapid computer simulations, artificial blood vessel testing systems, and cell culture techniques for investigating medications. Additionally, there is a growing emphasis on in vitro testing methods, online patient drug registries, virtual drug trial simulations, non-invasive imaging technologies like magnetic resonance imaging (MRI) and computed tomography (CT) scans, micro-dosing, and other innovative approaches.

The development and adoption of these techniques have the potential to influence the utilization of humanized mouse models, as researchers seek ways to reduce the costs associated with drug testing. Furthermore, there is a possibility that products not tested on animals may gain traction, driven by marketing efforts positioning them as environmentally friendly. These factors are expected to act as constraints on the expansion of the humanized mouse model market in the foreseeable future.

Humanized Mouse and Rat Model Market Segmentation 

By Type

On the basis of type, the market is segmented into genetic humanized mouse models and cell-based humanized mouse models. The genetic humanized mouse models segment is poised to emerge as the dominant force in the market. This prominence is primarily driven by the widespread adoption of genetically humanized mouse models in a variety of experimental studies, particularly when assessing the effectiveness and safety of substances. The increasing utilization of these mouse models for studying drug metabolism and disposition further amplifies the revenue growth in the humanized mouse model market.

The significance of the genetic humanized mouse model segment lies in its pivotal role in expediting drug discovery and development. Pharmaceutical and biotechnology companies, as well as research organizations, continue to actively rely on genetic humanized mouse models as a cornerstone for experimental analysis and drug development. This reinforces their position as a major revenue driver within the industry.

By Application

Regarding the application breakdown, the Humanized Mouse and Rat Model market is categorized into Oncology, Immunology, Neuroscience, Toxicology, Infectious Diseases and other applications.

The oncology segment is at the forefront of driving the expansion of the humanized mouse model market. Oncology research, which plays a leading role in comprehending cancer biology, devising novel treatments, and evaluating medication efficacy, heavily relies on humanized mouse models. These models facilitate more precise and reliable preclinical research by closely replicating the human tumour microenvironment.

Given the urgent need for cutting-edge cancer research and the development of new treatments, the oncology segment maintains its leadership position. The demand for humanized mouse models in this field is expected to remain robust as long as cancer continues to pose a significant global health challenge. This sustained demand is likely to stimulate progress and innovation in cancer therapies.

By Regions

By region, the market is divided into North America, Europe, APAC, and Others. Others is further divided into Middle East and South America.

The humanized mouse model market in North America is poised for significant growth. This trend is driven by the increasing demand for personalized medicine, with drug development necessitating the use of humanized mouse models for preclinical research. Advancements in genetic engineering and genome editing techniques have made it possible to create more precise and relevant humanized mouse models. Pharmaceutical companies and academic institutions in North America are increasingly relying on these models to study human diseases and evaluate potential treatments. The region's robust healthcare system and substantial financial investments in biomedical research contribute to the promising future of the mouse model market in North America.

Similarly, the European rat and mouse model market has a positive outlook, owing to its crucial role in advancing biomedical research and drug discovery. The adoption of humanized mouse models is gaining momentum in this region due to a strong commitment to cutting-edge research and healthcare innovation. Developments in gene editing technologies have significantly improved the accuracy and relevance of these models. European pharmaceutical companies and academic institutions are increasingly using humanized mouse models to study diseases, assess potential treatments, and develop personalized medicine approaches. The European market benefits from a robust healthcare infrastructure and substantial investments in the life sciences industry, solidifying its position as a hub for the development of humanized mouse models.

In the Asia Pacific region, the humanized mouse model market is expected to experience rapid growth in the coming years. This growth is driven by the thriving pharmaceutical and biotechnology sectors and a growing focus on precision medicine, leading to increased use of humanized mouse models in preclinical research. Advances in genetic engineering and genome editing techniques have resulted in more sophisticated and relevant models, enhancing their utility in disease modelling and drug testing. Academic institutions, research organizations, and pharmaceutical companies in Asia Pacific are increasingly integrating these models into their research workflows. The Asia Pacific region is emerging as a key player in the global humanized mouse model market, with significant potential for innovation and scientific advancement, supported by a growing healthcare infrastructure and increased investments in the life sciences industry.

Competitive Landscape of Humanized Mouse and Rat Model Market

The humanized mouse model industry is characterized by a dynamic and diverse competitive landscape, primarily due to the increasing demand for preclinical research tools in immunology and drug development. These companies employ genetic modification techniques such as CRISPR/Cas9 to create customized mouse models and offer a wide array of humanized mouse models and associated services. Collaborations with pharmaceutical and biotechnology companies for disease modelling and drug testing further intensify the competition in this sector. Emerging manufacturers of humanized mouse models are entering the market, fostering innovation and healthy competition.

The market ecosystem for humanized mouse and rat models encompasses product providers and end users, including Pharmaceutical & Biotechnology companies, Academic & Research Institutes, and CROs & CDMOs. Suppliers of these models offer them for various applications such as Preclinical Drug Development, Biomarker Analysis, and Cancer Research, among others. In essence, the market ecosystem for humanized mouse and rat models represents a multifaceted and ever-evolving network of diverse participants collaborating to advance biomedical research and enhance the development of improved therapies for human diseases. The prominent players present in the global marketplace are Harbour Antibodies BV, Champions Oncology Inc., Hera Biolabs, Charles River Laboratories, Crown Bioscience Inc., Ingenious Targeting Laboratory, Genoway S.A., Inotiv, Horizon Discovery Group Plc, Oncodesign and Humurine Technologies among others.

Recent Developments in the Humanized Mouse and Rat Model Market

• In January 2022, Taconic Biosciences, a leading provider of animal models for drug research, introduced the huNOG-EXL EA humanized immune system (HIS) mouse. This addition expands Taconic's well-established HIS portfolio and significantly extends the research capabilities of myeloid-lineage HIS mouse models.
• In October 2021, The Jackson Laboratory (JAX), a nonprofit biomedical research organization, announced its acquisition of the Research Models & Services (RMS) division of Charles River Laboratories Japan, establishing it as a wholly-owned subsidiary. The newly formed entity, The Jackson Laboratory Japan, is based in Japan and employs approximately 250 staff members across three production facilities in Atsugi, Hino, and Tsukuba, along with an administrative office in Yokohama.
• In September 2021, GenOway, a biotechnology company specializing in the design and development of preclinical models, acquired Axenis. Axenis focuses on creating immunocompromised models for validating novel and innovative therapies, complementing genOway's expertise.
• In November 2020, The Jackson Laboratory and Beijing Anitech Biotechnology revealed a collaborative partnership aimed at enhancing accessibility and expediting the delivery of high-quality research models and services in China.

Table of Contents

1.    Executive summary

2.    MARKET INTRODUCTION

2.1               MARKET SCOPE

2.2               MARKET Definitions

3.    research methodology

4.    market outlook

4.1               Key Trends

4.2               GUIDELINES / REGULATIONS

4.3               COVID-19 IMPACT ON GLOBAL HUMANIZED MOUSE AND RAT MODEL MARKET

4.4               MARKET DYNAMICS

4.4.1                   Drivers

4.4.1.1               Rising demand for personalized medicine

4.4.1.2               Ongoing support for cancer research

4.4.1.3               Growth of biotechnology and pharmaceutical industries

4.4.2                   Restraints

4.4.2.1               Expensive custom humanized models

4.4.2.2               Strict regulations for ethical use of animal models in research

4.4.3                   Opportunities

4.4.3.1               Development of CRISPR as a potent tool for biomedical research

4.4.4                   Challenges

4.4.4.1               Alternatives available for using animals in testing

4.5               PriCing Analysis

4.6               PORTER’S FIVE FORCE MODEL

4.6.1                   Threat of new entrants

4.6.2                   Threat of substitute

4.6.3                   Bargaining power of suppliers

4.6.4                   Bargaining power of buyers

4.6.5                   Intensity of competitive rivalry

5.    GLOBAL HUMANIZED MOUSE AND RAT MODEL MARKET, By TYPE, MARKET ESTIMATION AND FORECAST, 2022-2032), value (USD million)

5.1               INTRODUCTION

5.2               MARKET SHARE ANALYSIS

5.3               Genetic models

5.4               cell-based models

5.4.1                   CD34

5.4.2                   BLT

5.4.3                   PMC

5.5               RAT MODELS

6.    GLOBAL HUMANIZED MOUSE AND RAT MODEL MARKET, By Application, MARKET ESTIMATION AND FORECAST, 2022-2032), value (USD million)

6.1               INTRODUCTION

6.2               MARKET SHARE ANALYSIS

6.3               oncology

6.4               immunology

6.5               neuroscience

6.6               toxicology

6.7               infectious diseases

6.8               other applications

7.    GLOBAL HUMANIZED MOUSE AND RAT MODEL MARKET, BY End-User, MARKET ESTIMATION AND FORECAST, 2022-2032, value (USD million)

7.1               INTRODUCTION

7.2               pharma

7.3               biotech

7.4               academic & research institutes

8.    GLOBAL HUMANIZED MOUSE AND RAT MODEL MARKET, REGIONAL ANALYSIS MARKET ESTIMATION AND FORECAST, 2022-2032, value (USD million)

8.1               INTRODUCTION

8.2               NORTH AMERICA HUMANIZED MOUSE AND RAT MODEL MARKET

8.2.1                   North America Humanized Mouse And Rat Model  Market, By Country

8.2.1.1               US

8.2.1.2               Canada

8.2.1.3               Mexico

8.2.2                   North America Humanized Mouse and Rat Model  Market, By Type

8.2.3                   North America Humanized Mouse and Rat Model  Market, By Application

8.2.4                   North America Humanized Mouse and Rat Model  Market, By End-User

8.3               EUROPE HUMANIZED MOUSE AND RAT MODEL MARKET

8.3.1                   Europe Humanized Mouse and Rat Model  Market, By Country

8.3.1.1               Germany

8.3.1.2               UK

8.3.1.3               France

8.3.1.4               Italy

8.3.1.5               Spain

8.3.1.6               Russia

8.3.1.7               Rest of Europe

8.3.2                   Europe Humanized Mouse and Rat Model  Market, By Type

8.3.3                   Europe Humanized Mouse and Rat Model  Market, By Application

8.3.4                   Europe Humanized Mouse and Rat Model  Market, By End-User

8.4               ASIA PACIFIC HUMANIZED MOUSE AND RAT MODEL MARKET

8.4.1                   Asia Pacific Humanized Mouse and Rat Model Market, By Country

8.4.1.1               China

8.4.1.2               Japan

8.4.1.3               India

8.4.1.4               Australia

8.4.1.5               Singapore

8.4.1.6               South Korea

8.4.1.7               Thailand

8.4.1.8               Indonesia

8.4.1.9               Malaysia

8.4.1.10           Philippines

8.4.1.11           Rest of Asia Pacific

8.4.2                   Asia Pacific Humanized Mouse and Rat Model  Market, By Type

8.4.3                   Asia Pacific Humanized Mouse and Rat Model  Market, By Application

8.4.4                   Asia Pacific Humanized Mouse and Rat Model  Market, By End-User

8.5               MIDDLE EAST & AFRICA HUMANIZED MOUSE AND RAT MODEL MARKET

8.5.1                   Middle East & Africa Humanized Mouse and Rat Model  Market, By Country

8.5.1.1               UAE

8.5.1.2               Saudi Arabia

8.5.1.3               South Africa

8.5.1.4               Rest of Middle East & Africa

8.5.2                   Middle East & Africa Humanized Mouse and Rat Model  Market, By Type

8.5.3                   Middle East & Africa Humanized Mouse and Rat Model  Market, By Application

8.5.4                   Middle East & Africa Humanized Mouse and Rat Model  Market, By End-User

8.6               SOUTH AMERICA HUMANIZED MOUSE AND RAT MODEL  MARKET

8.6.1                   South America Humanized Mouse and Rat Model Market, By Country

8.6.1.1               Brazil

8.6.1.2               Argentina

8.6.1.3               Peru

8.6.1.4               Rest of South America

8.6.2                   South America Humanized Mouse and Rat Model  Market, By Type

8.6.3                   South America Humanized Mouse and Rat Model  Market, By Application

8.6.4                   South America Humanized Mouse and Rat Model  Market, By End-User

9.    GLOBAL HUMANIZED MOUSE AND RAT MODEL MARKET, COMPETITIVE Intelligence

9.1               COMPETITIVE POSITIONING

9.2               competitor benchmarking

9.3               Competitive Quadrant

9.4               market share analysis, 2022 (%)

10. GLOBAL HUMANIZED MOUSE AND RAT MODEL MARKET, COMPANY ANALYSIS

10.1           Axenis S.A.S

10.1.1               Company Overview

10.1.1.1           Business outlook

10.1.1.2           Headquarter

10.1.1.3           Established/Incorporated

10.1.1.4           Headcounts/ Employee strength

10.1.2               Financial Overview

10.1.2.1           Sales/revenue

10.1.2.2           R&D expenditure

10.1.2.3           Business segment sales share

10.1.2.4           Regional sales share

10.1.3               Product Offerings 

10.1.4               SWOT Analysis

10.1.5               Key Developments (Expansion/New Product Development/Agreement/Mergers & Acquisitions, Partnership/Investment/Etc.)

10.2           Champions Oncology Inc.

10.3           charles river laboratories

10.4           Crown Bioscience Inc.

10.5           Genoway S.A.

10.6           harbour antibodies BV

10.7           Hera biolabs

10.8           Horizon Discovery Group PLC

10.9           HuMurine Technologies

10.10        Ingenious Targeting Laboratory

10.11        inotiv

10.12        oncodesign

10.13        pharmatest services

10.14        Taconic Biosciences Inc.

10.15        The Jackson Laboratory

10.16        Trans Genic Inc.

10.17        Vitalstar Biotechnology Co. Ltd.

10.18        OTHERS

*Financials and Details May Not be Included in Case of Privately Held Company

Global Humanized Mouse and Rat Model Market Segmentation

Humanized Mouse and Rat Model by Model Type: Market Size & Forecast 2023-2030

• PDX (Patient-Derived Xenograft)
• Knock-in/Knock-out
• BAC (Bacterial Artificial Chromosome) Transgenic
• Cytokine-Humanized
• Immune-Humanized (liver, bone marrow, etc.)
• Other

Humanized Mouse and Rat Model by Application: Market Size & Forecast 2023-2030

• Oncology
• Immunology & Inflammation
• Infectious Diseases
• Metabolic Diseases
• CNS & Neurodegenerative Diseases
• Drug Discovery & Development
• Toxicology & Safety Testing
• Other

Humanized Mouse and Rat Model by Technology: Market Size & Forecast 2023-2030

• CRISPR-Cas9
• Humanized Immune System Engineering (huMICE)
• Microbiome Humanization
• Organ-on-a-Chip
• Other

Humanized Mouse and Rat Model by End User: Market Size & Forecast 2023-2030

• Pharmaceutical & Biotechnology Companies
• Contract Research Organizations (CROs)
• Academic & Research Institutions
• Government Agencies & Regulatory Bodies
• Other

Humanized Mouse and Rat Model by Geography: Market Size & Forecast 2023-2030

• North America (USA, Canada, Mexico)
• Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
• Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
• South America (Brazil, Argentina, Columbia, Rest of South America)
• Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

Major Players:

• The Jackson Laboratory
• Taconic Biosciences, Inc.
• Charles River Laboratories International, Inc.
• Janvier Labs
• genOway S.A.
• Ingenious Targeting Laboratory, Inc.
• Horizon Discovery Group plc
• Hera BioLabs, Inc.
• Trans Genic Inc.
• Crown Bioscience Inc.
• Envigo RMS LLC
• Biomere
• Harbour Antibodies BV
• Champions Oncology, Inc.
• Vitalstar Biotechnology Co., Ltd.
• Axenis S.A.S.
• Biocytogen LLC
• Beijing Vitalstar Biotechnology Co., Ltd.
• SAGE Labs, Inc. (part of Horizon Discovery Group plc)
• InVivos Pte. Ltd.
• Ozgene Pty Ltd.
• Transposagen Biopharmaceuticals, Inc.
• genoway (a Subsidiary of genOway S.A.)
• Synthego Corporation